Neuraceq® reliably visualizes β-amyloid neuritic plaques, supporting accurate diagnosis and treatment planning in Alzheimer’s disease.
FDA approved for amyloid plaque quantification and patient selection for amyloid-targeting therapies.*
A precise diagnostic tool is needed to reduce the time to accurate diagnosis
US-Neuraceq-24-00011
The information contained in Neuraceq.com/hcp is intended for healthcare professionals in the United States only. If you are a US healthcare professional, click the "Continue" button below.
Yes, I am a US healthcare professional and would like to continue.
This will close in 0 seconds
PRODUCT INDICATIONS AND USE: NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.
NEURACEQ IMPORTANT SAFETY INFORMATION:
CONTRAINDICATIONS: None
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS:
USE IN SPECIFIC POPULATIONS:
OVERDOSAGE:
In the event of administration of a radiation overdose with NEURACEQ, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to NEURACEQ administration, please read the full Prescribing Information for additional Important Safety Information.
SUSPECTED ADVERSE REACTIONS: please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
